A Study of Dotinurad Versus Allopurinol in Participants With Gout
A Phase 3, Randomized, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of Dotinurad Compared With Allopurinol in Adult Participants With Hyperuricemia Associated With Gout
Crystalys Therapeutics
500 participants
Aug 1, 2025
INTERVENTIONAL
Conditions
Summary
The primary objective of this study is to evaluate the efficacy of dotinurad in lowering serum uric acid (sUA) at Week 24 compared with allopurinol in adult participants with hyperuricemia associated with gout.
Eligibility
Plain Language Summary
Simplified for easier understanding
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Over-encapsulated tablets containing active drug substance administered orally (PO).
Over-encapsulated tablets containing active drug substance administered PO.
Locations(100)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07089875